IT TECH PACKAGING, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IT TECH PACKAGING, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $75.84M | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | $86.55M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $100.35M | Mar 27, 2024 |
| FY2021 | Dec 31, 2021 | $45.05M | Mar 15, 2022 |
| FY2021 | Sep 30, 2021 | $45.09M | Mar 15, 2022 |
| FY2021 | Jun 30, 2021 | $46.53M | Mar 15, 2022 |
| FY2021 | Mar 31, 2021 | $24.21M | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | $32.48M | Mar 15, 2022 |
| FY2021 | Sep 30, 2020 | $33.36M | Mar 15, 2022 |
| FY2021 | Jun 30, 2020 | $26.36M | Mar 15, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.69M | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | $999.9K | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $4.75M | Mar 27, 2024 |
| FY2021 | Dec 31, 2021 | $4.34M | Mar 15, 2022 |
| FY2021 | Sep 30, 2021 | $1.82M | Mar 15, 2022 |
| FY2021 | Jun 30, 2021 | $3.03M | Mar 15, 2022 |
| FY2021 | Mar 31, 2021 | $1.83M | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | $745.3K | Mar 15, 2022 |
| FY2021 | Sep 30, 2020 | $2.57M | Mar 15, 2022 |
| FY2021 | Jun 30, 2020 | $2.56M | Mar 15, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($9.84M) | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | ($9.95M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($16.57M) | Mar 27, 2024 |
| FY2021 | Dec 31, 2021 | $4.16M | Mar 15, 2022 |
| FY2021 | Sep 30, 2021 | $1.54M | Mar 15, 2022 |
| FY2021 | Jun 30, 2021 | ($453.2K) | Mar 15, 2022 |
| FY2021 | Mar 31, 2021 | ($4.34M) | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | ($1.62M) | Mar 15, 2022 |
| FY2021 | Sep 30, 2020 | ($521.0K) | Mar 15, 2022 |
| FY2021 | Jun 30, 2020 | ($980.0K) | Mar 15, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($8.21M) | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | ($9.58M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($5.30M) | Mar 27, 2024 |
| FY2021 | Dec 31, 2021 | $1.95M | Mar 15, 2022 |
| FY2021 | Sep 30, 2021 | ($198.0K) | Mar 15, 2022 |
| FY2021 | Jun 30, 2021 | $431.4K | Mar 15, 2022 |
| FY2021 | Mar 31, 2021 | ($724.3K) | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | ($1.97M) | Mar 15, 2022 |
| FY2021 | Sep 30, 2020 | $176.6K | Mar 15, 2022 |
| FY2021 | Jun 30, 2020 | ($798.6K) | Mar 15, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $99.6K | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | $90.8K | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $145.5K | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $101.4K | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $69.2K | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $74.8K | Apr 19, 2021 |
| FY2019 | Dec 31, 2018 | $30.2K | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $31.9K | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $21.6K | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $28.4K | Mar 22, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $14.80M | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | $9.08M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $10.06M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $9.56M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $11.16M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $9.78M | Apr 19, 2021 |
| FY2019 | Dec 31, 2018 | $13.10M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $11.31M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $12.40M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $9.66M | Mar 22, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.30M | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | $12.87M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $10.72M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($2.44M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $16.14M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $7.53M | Apr 19, 2021 |
| FY2019 | Dec 31, 2018 | $9.17M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $18.15M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $15.28M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $21.20M | Mar 22, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $329.6K | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | $22.29M | Apr 11, 2025 |
| FY2022 | Dec 31, 2022 | $4.53M | Mar 24, 2023 |
| FY2022 | Dec 31, 2021 | $25.07M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $21.11M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $6.42M | Apr 19, 2021 |
| FY2018 | Dec 31, 2018 | $2.20M | Mar 7, 2019 |
| FY2018 | Dec 31, 2017 | $9.38M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $11.59M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $19.33M | Mar 22, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $177.55M | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | $194.74M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $204.45M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $241.54M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $199.87M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $190.20M | Apr 19, 2021 |
| FY2019 | Dec 31, 2018 | $203.08M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $218.99M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $208.38M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $238.63M | Mar 22, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $21.50M | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | $26.41M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $23.12M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $25.79M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $24.79M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $24.20M | Apr 19, 2021 |
| FY2019 | Dec 31, 2018 | $36.53M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $33.66M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $35.62M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $62.82M | Mar 22, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $156.05M | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | $168.34M | Apr 11, 2025 |
| FY2024 | Dec 31, 2022 | $181.32M | Apr 11, 2025 |
| FY2023 | Dec 31, 2021 | $215.75M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $175.08M | Mar 24, 2023 |
| FY2021 | Dec 31, 2019 | $166.00M | Mar 15, 2022 |
| FY2019 | Dec 31, 2018 | $166.55M | Mar 23, 2020 |
| FY2019 | Dec 31, 2017 | $185.33M | Mar 23, 2020 |
| FY2018 | Dec 31, 2016 | $172.76M | Mar 7, 2019 |
| FY2017 | Dec 31, 2015 | $175.81M | Apr 17, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $73.79M | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | $83.63M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $93.58M | Mar 27, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $12.12M | Mar 7, 2019 |
| FY2018 | Dec 31, 2017 | $9.02M | Mar 7, 2019 |
| FY2018 | Dec 31, 2016 | $4.49M | Mar 7, 2019 |
| FY2017 | Dec 31, 2015 | $2.64M | Apr 17, 2018 |
| FY2015 | Dec 31, 2014 | $3.89M | Mar 23, 2016 |
| FY2015 | Dec 31, 2013 | $3.13M | Mar 23, 2016 |
| FY2015 | Dec 31, 2012 | $13.14M | Mar 23, 2016 |
| FY2014 | Dec 31, 2011 | $4.17M | Mar 25, 2015 |
| FY2013 | Dec 31, 2010 | $11.35M | Mar 25, 2014 |
| FY2012 | Dec 31, 2009 | $6.95M | Mar 18, 2013 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.67M | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | $11.38M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $9.04M | Mar 27, 2024 |
| FY2021 | Dec 31, 2021 | $9.82M | Mar 15, 2022 |
| FY2020 | Dec 31, 2020 | $9.59M | Apr 19, 2021 |
| FY2019 | Dec 31, 2019 | $4.44M | Mar 23, 2020 |
| FY2019 | Dec 31, 2019 | 31.00M | Mar 23, 2020 |
| FY2019 | Dec 31, 2018 | 31.00M | Mar 23, 2020 |
| FY2019 | Dec 31, 2018 | $4.52M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $8.16M | Mar 7, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 27, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 15, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 15, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Mar 15, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 27, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 15, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 15, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Mar 15, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 10.07M | Apr 11, 2025 |
| FY2024 | Dec 31, 2023 | 10.07M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | 10.07M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 9.92M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | 28.54M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 22.05M | Apr 19, 2021 |
| FY2018 | Dec 31, 2018 | 20.02M | Mar 7, 2019 |
| FY2018 | Dec 31, 2017 | 21.45M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 21.45M | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | 20.32M | Mar 22, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2013 | $323.0K | Mar 23, 2016 |
| FY2014 | Dec 31, 2012 | $692.2K | Mar 25, 2015 |